Undisclosed Transcription Factor
Solid Tumor
Key Facts
About Talus Bioscience
Talus Bioscience is an early-stage biotech leveraging a proprietary platform to make the regulome, a previously hidden layer of gene control, accessible for drug discovery. Its technology combines AI-designed chemical libraries, high-throughput functional proteomics, and machine learning models to identify and drug transcription factors and other regulatory proteins implicated in disease. The company is advancing an internal pipeline of first-in-class programs in oncology and immunology while also exploring strategic partnerships to expand its reach.
View full company profileAbout Talus Bioscience
Talus Bioscience is an early-stage biotech leveraging a proprietary platform to make the regulome, a previously hidden layer of gene control, accessible for drug discovery. Its technology combines AI-designed chemical libraries, high-throughput functional proteomics, and machine learning models to identify and drug transcription factors and other regulatory proteins implicated in disease. The company is advancing an internal pipeline of first-in-class programs in oncology and immunology while also exploring strategic partnerships to expand its reach.
View full company profileTherapeutic Areas
Other Solid Tumor Drugs
| Drug | Company | Phase |
|---|---|---|
| AV-203 | AVEO Oncology | Pre-clinical |
| LR19155 | AVEO Oncology | Pre-clinical |
| LR20011 | AVEO Oncology | Pre-clinical |
| LR19129 | AVEO Oncology | Pre-clinical |
| LR19023 | AVEO Oncology | Pre-clinical |
| RGI-AB-01 | REGiMMUNE | Preclinical |
| RGI-AB-02 | REGiMMUNE | Preclinical |
| RGI-AB-03 | REGiMMUNE | Preclinical |
| RGI-AB-04 | REGiMMUNE | Preclinical |
| CS028 | Lumosa Therapeutics | Pre‑clinical |